文献速递妇科

II期子宫内膜癌前哨淋巴结活检:美国近期应用与结局

Sentinel lymph node biopsy for stage II endometrial cancer: Recent utilization and outcome in the United States.
PubMed 文献 · Gynecol Oncol · 2021-10-30

该回顾性观察队列研究基于美国SEER数据库2010-2018年6314例T2子宫内膜癌子宫切除患者,分析前哨淋巴结活检(SLN)的应用趋势与总生存。SLN活检使用率从1.6%升至16.1%,淋巴结清扫从81.5%降至65.7%,多因素分析显示SLN活检使用率每年增加45%;加权模型中SLN活检组与淋巴结清扫组3年OS率分别为79.9%与78.6%,无显著差异。

要点

  • 2010-2018年II期子宫内膜癌中SLN活检使用率从1.6%升至16.1%,淋巴结清扫从81.5%降至65.7%。
  • 多因素分析显示SLN活检使用率每年增加45%(aOR 1.45,95%CI 1.37-1.54,P<0.001)。
  • 加权模型中SLN活检组与淋巴结清扫组3年OS率分别为79.9%与78.6%,无显著差异(HR 0.98,95%CI 0.80-1.20,P=0.831)。

核心结论

  • II期子宫内膜癌中SLN活检使用率随时间显著增加,纳入SLN活检的淋巴结评估与短期生存结局恶化无关。

研究设计与样本

  • 回顾性观察队列研究,查询美国国家癌症研究所SEER项目,纳入2010-2018年接受子宫切除术的6314例T2子宫内膜癌女性。
  • 按淋巴结评估方式分组:淋巴结清扫组4915例(77.8%)、SLN活检组340例(5.4%)、未行手术淋巴结评估组1059例(16.8%)。
  • 主要结局为淋巴结评估相关趋势与特征(多项回归分析)及总生存(逆概率治疗加权倾向评分分析),并对SLN活检中同期行淋巴结清扫者进行敏感性分析。

主要发现

  • 2010-2018年间SLN活检使用率从1.6%升至16.1%,淋巴结清扫从81.5%降至65.7%(P<0.05)。
  • 多因素分析中SLN活检使用率每年增加45%(调整比值比1.45,95%CI 1.37-1.54,P<0.001)。
  • 2017年单纯SLN活检频率超过SLN活检联合同期淋巴结清扫(6.8% vs 3.4%),2018年单纯SLN活检继续增加(11.2% vs 4.9%)。
  • 加权模型中SLN活检组与淋巴结清扫组3年OS率分别为79.9%与78.6%(风险比0.98,95%CI 0.80-1.20,P=0.831)。
  • 单纯SLN活检未联合淋巴结清扫者与淋巴结清扫组OS相当(风险比0.90,95%CI 0.59-1.36,P=0.615)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine trends and outcomes related to sentinel lymph node (SLN) biopsy for stage II endometrial cancer. METHODS: This is a retrospective observational cohort study querying the National Cancer Institute's Surveillance, Epidemiology, and End Results Program. The study population was 6,314 women with T2 endometrial cancer who underwent hysterectomy from 2010-2018. Exposure allocation was based on nodal evaluation type: lymphadenectomy (LND; n=4,915, 77.8%), SLN biopsy (n=340, 5.4%), or no surgical nodal evaluation (n=1,059, 16.8%). The main outcomes were (i) trends and characteristics related to nodal evaluation assessed by multinomial regression, and (ii) overall survival (OS) assessed by an inverse probability of treatment weighting propensity score analysis. A sensitivity analysis was performed to examine concurrent LND in women who underwent SLN biopsy. RESULTS: The utilization of SLN biopsy increased from 1.6% to 16.1%, while the number of LND decreased from 81.5% to 65.7% between 2010-2018 (P<0.05). In multivariable analysis, the utilization of SLN biopsy increased 45% annually (adjusted-odds ratio 1.45, 95% confidence interval [CI] 1.37-1.54, P<0.001). The frequency of SLN biopsy alone exceeded the frequency of SLN biopsy with concurrent LND in 2017 (6.8% versus 3.4%), followed by continued increase in SLN biopsy alone (11.2% versus 4.9%) in 2018. In the weighted model, the 3-year OS rate was 79.9% for the SLN biopsy group and 78.6% for the LND group (hazard ratio 0.98, 95%Cl 0.80-1.20, P=0.831). Similarly, the SLN biopsy alone without concurrent LND had comparable OS compared to the LND group (hazard ratio 0.90, 95%CI 0.59-1.36, P=0.615). CONCLUSION: Utilization of SLN biopsy in stage II endometrial cancer increased significantly over time, and SLN biopsy-incorporated nodal assessment was not associated with worsened short-term survival outcome.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Matsuo K, Klar M, Khetan VU, et al. Sentinel lymph node biopsy for stage II endometrial cancer: Recent utilization and outcome in the United States. Gynecol Oncol. 2021. PMID: 34728108. doi:10.1016/j.ygyno.2021.10.085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。